Primary prevention and screening in adult: Update 2006;Prévention primaire et dépistage chez l'adulte: Mise à jour 2006

Revue Medicale Suisse

Volumn 2, Issue 50, 2006, Pages 262-273

  Cornuz, Jacques ^a,b   Guessous, Idris ^b   Rodondi, Nicolas ^a  

^a POLICLINIQUE MÉDICALE UNIVERSITAIRE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROSTATE SPECIFIC ANTIGEN; VITAMIN;

ABDOMINAL AORTA ANEURYSM; ABDOMINAL RADIOGRAPHY; ATHEROSCLEROTIC PLAQUE; BREAST CANCER; CANCER; CANCER DIAGNOSIS; CANCER SCREENING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CIGARETTE SMOKING; CLINICAL TRIAL; COLONOSCOPY; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY DISEASE; COUNSELING; DIABETES MELLITUS; DIET THERAPY; DIGITAL RECTAL EXAMINATION; DYSLIPIDEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTHYROIDISM; IMMUNIZATION; LUNG CANCER; MAMMOGRAPHY; OBESITY; OVARY CANCER; PANCREAS CANCER; PERIPHERAL VASCULAR DISEASE; PHYSICAL ACTIVITY; PROPHYLAXIS; PROSTATE CANCER; REVIEW; SCREENING TEST; THORAX RADIOGRAPHY; THYROID DISEASE; TRANSVAGINAL ECHOGRAPHY; UTERUS CANCER; ADULT; AGE; AGED; BREAST TUMOR; FEMALE; HEALTH SURVEY; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASM; PRACTICE GUIDELINE; PRIMARY PREVENTION; RISK FACTOR; SMOKING;

ADULT; AGE FACTORS; AGED; AORTIC ANEURYSM, ABDOMINAL; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASMS; POPULATION SURVEILLANCE; PRACTICE GUIDELINES; PRIMARY PREVENTION; RISK FACTORS; SMOKING;

EID: 33645210667     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Cornuz J, Gervasoni JP, Hengstler P, et al. Prévention primaire et dépistage chez l'adulte: quelles sont les priorités en 2002? Med Hyg 2002;60:2008-16.
2. Aujesky D, Cornuz J. Physiopathologie, observations cliniques et essais cliniques randomisés: quelle complémentarité? Med Hyg 2004;62:2358-62.
3. Yarnall KS, Pollak KI, Ostbye T et al. Primary care: Is there enough time for prevention? Am J Public Health 2003;93:635-41.
4. Cornuz J, Etienne S, Giorgis B, et al. Prévention en pratique médicale ambulatoire. Un guide de prévention et de promotion de la santé chez les patients de 50 ans consultant un médecin de premier recours. Lausanne: Institut universitaire de médecine sociale et préventive - Raisons de santé, 2002; n° 74.
5. Ezzati M, Lopez AD, Rodgers A, et al. Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002;360:1347-60.
6. Crichley JA Capewell S. Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: A systematic review. JAMA 2003;290:86-97.
7. Grimes DA, Schulz KF. Uses and abuses of screening tests. Lancet 2002;359:881-4.
8. Gotzsche PC, Olsen O. Is screening for breast cancer with mammography justifiable? Lancet 2000;355:129-34.
9. Olsen O, Gotzsche PC. Cochrane review on screening for breast cancer with mammography. Lancet 2001;358:1340-2.
10. Levi F, Lucchini F, Negri E, et al. The fall in breast cancer mortality in Europe. Eur J Cancer 2001;37:1409-12.
11. Humphrey LL, Helfand M, Chan BK, et al. Breast cancer screening: A summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002;137:347-60.
12. Tabar L, Yen MF, Vitak B, et al. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet 2003;361:1405-10.
13. Otto SJ, Fracheboud J, Looman CW, et al. National evaluation team for breast cancer screening. Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: A systematic review. Lancet 2003;361:1411-7.
14. Leach MO, Boggis CR, Dixon AK, et al. MARIBS study group. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: A prospective multicentre cohort study (MARIBS). Lancet 2005;365:1769-78.
15. Kriege M, Brekelmans CT, Boetes C, et al. Magnetic Resonance Imaging Screening Study Group. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004;351:427-37.
16. Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in the United States: Does practice reflect the evidence? JAMA 2003;289:1414-20.
17. Osborn NK, Ahlquist DA. Stool screening for colorectal cancer: Molecular approaches. Gastroenterology 2005;128:192-206.
18. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Colorectal Cancer Study Group. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004;351:2704-14.
19. Townsend CO, Clark MM, Jett JR, et al. Relation between smoking cessation and receiving results from three annual spiral chest computed tomography scans for lung carcinoma screening. Cancer 2005;103:2154-61
20. Prorok PC, Andriole GL, Bresalier RS, et al. Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000;21(Suppl. 6):273S-309S.
21. www.cancer.org/docroot/PED/content/
22. Makinen T, Tammela TL, Stenman UH, et al. A Family history and prostate cancer screening with prostate-specific antigen. J Clin Oncol 2002;20:2658-63.
23. Johns LE, Houlston RS. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int 2003;91:789-94.
24. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004;350:2239-46.
25. Harris R, Lohr KN. Screening for prostate cancer: An update of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002;137:917-29.
26. Mor G, Visintin I, Lai Y, et al. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci USA 2005;102:7677-82.
27. Sawaya GF, Grady D, Kerlikowske K, et al. The positive predictive value of cervical smears in previously screened postmenopausal women: The Heart and Estrogen/progestin Replacement Study (HERS). Ann Intern Med 2000;133:942-50.
28. Sirovich BE, Welch HG. Cervical cancer screening among women without a cervix. JAMA 2004;291:2990-3.
29. Walter LC, Lindquist K, Covinsky KE. Relationship between health status and use of screening mammography and Papanicolaou smears among women older than 70 years of age. Ann Intern Med 2004;140:681-8.
30. Sawaya GF, McConnell KJ, Kubsingam SL, et al. Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. N Engl J Med 2003;349:1501-9.
31. Norman PE, Semmens JB, Lawrence-Brown MM, et al. Long term relative survival after surgery for abdominal aortic aneurysm in western Australia: Population based study. BMJ 1998;317:852-6.
32. Fleming C, Whitlock EP, Beil TL, et al. Screening for abdominal aortic aneurysm: A best-evidence systematic review for the US Preventive Services Task Force. Ann Intern Med 2005;142:203-11.
33. Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 2003;289:2560-72.
34. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000;356:1955-64.
35. Riesen W, Darioli R, Noseda G, et al. Empfehlungen zur Prävention der Atherosklerose. Schweizerische Ärztezertung 2005;86:1355-61.
36. Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998;81:582-7.
37. Pitt B. Low-density lipoprotein cholesterol in patients with stable coronary heart disease-is it time to shift our goals? N Engl J Med 2005;352:1483-4.
38. Harris R, Donahue K, Rathore SS, et al. Screening adults for type 2 diabetes: A review of the evidence for the US Preventive Services Task Force. Ann Intern Med 2003;138:215-29.
39. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA 2001;285:2486-97.
40. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
41. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2002;25:213-29.
42. USPSTF. Screening for obesity in adults: Recommendations and rationale. Ann Intern Med 2003;139:930-2.
43. McTigue KM, Harris R, Hemphill B, et al. Screening and interventions for obesity in adults: Summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2003;139:933-49.
44. Helfand M. Screening for subclinical thyroid dysfunction in nonpregnant adults: A summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2004;140:128-41.
45. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: Scientific review and guidelines for diagnosis and management JAMA 2004;291:228-38.
46. Rodondi N, Vittinghoff E, de Rekeneire N, et al. Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Arch Intern Med 2005; in press.
47. Ladenson PW, Singer PA, Ain KB, et al. American Thyroid Association guidelines for detection of thyroid dysfunction. Arch Intern Med 2000;160:1573-5.
48. Pignone M, Fowler-Brown A, Pletcher MJ, et al. Screening for asymptomatic coronary artery disease: A systematic review for the US Preventive Services Task Force, Access on August 2005.
49. Ashley EA, Raxwal V, Froelicher V. An evidence-based review of the resting electrocardiogram as a screening technique for heart disease. Prog Cardiovasc Dis 2001;44:55-67.
50. Fowler-Brown A, Pignone M, Pletcher M, et al. Exercise tolerance testing to screen for coronary heart disease: A systematic review for the technical support for the US Preventive Services Task Force. Ann Intern Med 2004;140:W9-24.
51. O'Malley PG, Feuerstein IM, Taylor AJ. Impact of electron beam tomography, with or without case management, on motivation, behavioural change, and cardiovascular risk profile: A randomized controlled trial. JAMA 2003;289:2215-23.
52. USPSTF. Screening for peripheral arterial disease: Recommendation statement. www.ahrq.gov/clinic.2005.
53. USPSTF. Behavioral counseling to prevent tobacco use and tobacco-caused disease. Recommendation statement. US Preventive Services Task Force. www.ahrq. gov/clinic, 2005.
54. USPSTF. Behavioral counseling in primary care to promote a healthy diet: Recommendations and rationale. Am J Prev Med 2003;24:93-100.
55. USPSTF. Behavioral counseling in primary care to promote physical activity: Recommandation and rationale. Ann Intern Med 2002;137:205-7.
56. Pate RR, Pratt M, Blair SN, et al. Physical activity and public health. A recommendation from the Centers for disease control and prevention and the american college of sports medicine. JAMA 1995;273:402-7.
57. USPSTF. Aspirin for the primary prevention of cardiovascular events: Recommendation and rationale. Ann Intern Med 2002;136:157-60.
58. Ridker PM, Cook Nr, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-304.
59. Hayden M, Pignone M, Phillips C, et al. Aspirin for the primary prevention of cardiovascular events: A summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002;136:161-72.
60. Rodondi N, Cornuz J, Bauer DC. Aspirin for the primary prevention of cardiovascular disease: A comprehensive review. Compr Ther 2005, in press.
61. Rodondi N, Bauer DC. Assessing the risk/benefit profile before recommending aspirin for the primary prevention of cardiovascular events. Am J Med 2004;117:528-30.
62. Morris CD, Carson S. Routine vitamin supplementation to prevent cardiovascular disease: A summary of the evidence for the U S Preventive Services Task Force. Ann Intern Med 2003;139:56-70.
63. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994;330:1029-35.
64. Omenn GS, Goodman GE, Thornquist MD, et al. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 1006;88:1550-9.